Alzheimer's Disease Clinical Trials in Colorado

13 recruiting studies across 2 cities

Browse by City

All Trials in Colorado

Phase

Trial	Phase	Sponsor	Dist.
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)	Phase 3	Bristol-Myers Squibb	<1 mi
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)	Phase 3	Bristol-Myers Squibb	<1 mi
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)	Phase 3	Karuna Therapeutics, Inc., a Bristol Myers Squibb company	<1 mi
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)	Phase 3	Bristol-Myers Squibb	<1 mi
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)	Phase 3	Karuna Therapeutics, Inc., a Bristol Myers Squibb company	<1 mi
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase	N/A	University of Alabama, Tuscaloosa	5 mi
A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD	Phase 3	Annovis Bio Inc.	6 mi
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease	Phase 2	Celgene	8 mi
CBD for Individuals at Risk for Alzheimer's Disease	Phase 2	University of Colorado, Denver	8 mi
Intervention to Collect and Utilize Sexual Orientation and Gender Identity (SOGI) Information in Hospice	N/A	University of Colorado, Denver	8 mi
Trial-Ready Cohort-Down Syndrome (TRC-DS)	—	University of Southern California	8 mi
Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease	Phase 2	University of Colorado, Denver	8 mi
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant	Phase 3	Eidos Therapeutics, a BridgeBio company	8 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.